# Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease

> **NCT02503501** · PHASE2 · TERMINATED · sponsor: **HealthPartners Institute** · enrollment: 49 (actual)

## Conditions studied

- Mild Cognitive Impairment
- Alzheimer's Disease (AD)

## Interventions

- **DRUG:** Insulin glulisine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02503501
- **Lead sponsor:** HealthPartners Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-28
- **Primary completion:** 2019-02-11
- **Final completion:** 2019-02-15
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Study will not have power to show a difference between groups.
- **Last updated:** 2020-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02503501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02503501, "Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02503501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*